Welcome to our dedicated page for U S PHYSICAL THERAPY /NV SEC filings (Ticker: USPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on U S PHYSICAL THERAPY /NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into U S PHYSICAL THERAPY /NV's regulatory disclosures and financial reporting.
U.S. Physical Therapy reported an insider sale notice for common stock. The Form 144 shows Graham Reeve sold 1,808 shares on 03/10/2026 following the vesting of restricted stock grants issued for services rendered. The broker listed is J.P. Morgan Securities LLC.
U S Physical Therapy's Chief Financial Officer Carey P. Hendrickson reported a disposition of 10,000 shares of common stock back to the issuer. The Form 4 lists the transaction as a "Disposition to issuer" at a reported price of $0.00 per share, often indicating an administrative or compensation-related transfer rather than an open-market trade. Following this transaction, Hendrickson directly owns 27,808 shares of U S Physical Therapy common stock. A footnote explains that 11,070 of these shares are unvested restricted stock granted under the company’s stock incentive plan, scheduled to vest in tranches between May 20, 2026 and March 6, 2029, provided he remains employed on those dates.
U.S. Physical Therapy executive Richard Binstein, EVP, General Counsel and Secretary, sold 3,000 shares of common stock in an open-market transaction at $81.64 per share. After this sale, he directly owns 24,867 shares, including 21,070 restricted shares scheduled to vest in tranches between May 2026 and March 2030, subject to continued employment.
U.S. Physical Therapy, Inc. filed an 8-K to share an updated investor presentation for the year ended December 31, 2025. The deck highlights that the company owns or manages 780 outpatient physical and occupational therapy clinics across 44 states, generating $781mm in trailing twelve-month revenue and $95mm in trailing twelve-month Adjusted EBITDA.
The presentation describes a highly fragmented $40bn+ U.S. rehabilitation market where no single company holds more than 10% share, positioning USPh as one of the largest platforms. It reports 16% year-over-year revenue growth and a $1.80 annual dividend, driven by organic clinic openings and acquisitions in physical therapy and industrial injury prevention services.
US Physical Therapy reported a Rule 144 resale of 3,000 shares of Class A common stock related to the vesting of restricted stock grants issued through 08/20/2025. The sale is listed with J.P. Morgan Securities LLC and dated 03/06/2026, with an execution date shown as 03/09/2026.
U.S. Physical Therapy, Inc. reported strong operating momentum for 2025 and outlined growth plans for 2026 and beyond. Clinic visit volume rose 11.2% year over year, with average visits per clinic per day reaching a record 32.2, despite a 2.9% Medicare rate cut.
Net rate per visit increased from $104.71 in 2024 to $105.76 in 2025, while adjusted EBITDA grew 16.1% from $81.8M to $95M. In Q4 2025, physical therapy revenue was $173.8M, up 13%, and physical therapy adjusted gross margin improved to 20.5% from 18.6%.
The injury prevention segment delivered double-digit growth, with IIP income up 20.2% for the year. The company expects 2026 adjusted EBITDA of $102M–$106M and highlighted two new hospital affiliation agreements that, when fully implemented by year-end 2026, are expected to add at least $14M to physical therapy revenue and income and at least $7.3M to USPH adjusted EBITDA by 2027.
U.S. Physical Therapy, Inc. operates two main segments: a large outpatient physical therapy business and an industrial injury prevention (IIP) unit serving employers, including Fortune 500 companies. The company works mainly through therapist-partnered clinic partnerships, plus some wholly owned and hospital- or physician-managed locations.
As of December 31, 2025, it owned and/or managed 780 clinics in 44 states, including 34 hospital or physician-owned practices under management contracts. A clinic roll-forward shows steady net additions through acquisitions, satellite development and tuck-in deals, offset by periodic closures and sales.
Net patient revenue in 2025 was $650,429 (in thousands), with 48.5% from managed care/commercial insurance, 35.8% from Medicare/Medicaid, 10.2% from workers’ compensation and 5.5% from other sources. Medicare represented 40.1% of visits and is reimbursed under the MPFS, which decreased rates by about 1.5% in 2025, with a 1.75% increase expected for 2026.
The company has expanded through multiple multi-clinic and IIP acquisitions from 2023–2025, raising its stake in Briotix Health to about 92%, and continues to target outpatient PT and IIP businesses. It repurchased 81,322 shares for $5.6 million in Q4 2025 and is rolling out a new ERP system to improve integration and reporting.
USPH emphasizes compliance in a highly regulated environment, addressing Medicare, fraud-and-abuse, Stark Law, HIPAA, antitrust, and corporate practice restrictions through a formal compliance program, board-level oversight, audits and training. As of December 31, 2025 it employed about 7,294 people, plus 801 employees at therapist-owned practices it manages, and highlights workforce recruitment, retention and education as critical to its growth strategy.
U.S. Physical Therapy, Inc. reported strong growth for 2025, with net revenue rising to $781.0 million, up 16.3% from 2024, and gross profit increasing to $149.7 million. Full-year Adjusted EBITDA climbed to $95.0 million from $81.8 million, while non-GAAP Operating Results rose to $40.0 million, or $2.63 per share.
GAAP earnings per share declined to $1.42 from $1.84, largely due to the accounting impact of redeemable non-controlling interests. In the 2025 fourth quarter, net revenue grew to $202.7 million, Adjusted EBITDA reached $24.8 million, and non-GAAP Operating Results were $0.67 per share, though GAAP loss per share was $0.44.
The company expanded through acquisitions, ending 2025 with 780 clinics, and completed two deals in January 2026 adding physical therapy and industrial injury prevention revenue. It also entered two 10-year strategic hospital alliances expected to add at least $7.3 million in annualized EBITDA attributable to USPH once fully ramped.
Management issued 2026 Adjusted EBITDA guidance of $102–$106 million, reflecting expected Medicare rate benefits and early contributions from the new alliances. The Board raised the quarterly dividend to $0.46 per share and declared a payout for April 10, 2026. Chief Financial Officer Carey Hendrickson plans to resign effective April 24, 2026, with Senior Vice President Jason Curtis serving as interim CFO.
U.S. Physical Therapy, Inc. reported that Chairman and CEO Christopher J. Reading acquired 25,000 shares of common stock as a restricted stock grant under the company’s Amended and Restated 2003 Stock Incentive Plan. The award was recorded at a price of $0.00 per share as compensation, not an open-market purchase.
The restrictions on these 25,000 shares lapse in 15 equal quarterly installments of 1,562 shares beginning on May 20, 2026, with a final 1,570-share tranche vesting on March 6, 2030, subject to his continued employment. Following this grant, he directly holds 139,088 shares, including previously granted restricted stock with various vesting dates through 2030.